Product information

PDS0201 is a novel investigational tuberculosis vaccine that generates broad and robust antibody and T cell responses that provide durable protection against bacillus Mycobacterium tuberculosis (M. tuberculosis). PDS0202 is given as a single dose by intramuscular injection and is being developed to provide robust and durable protection against tuberculosis.

Disease state

Tuberculosis (TB) is the leading cause of death from a single infectious agent and is caused by the bacillus Mycobacterium tuberculosis, which is spread when people who are sick with TB expel bacteria into the air. About a quarter of the world’s population is infected with M. tuberculosis and thus at risk of developing TB disease. It has been reported that a total of 1.5 million people died from TB in 2018. Worldwide, TB is one of the top 10 causes of death and the leading cause from a single infectious agent (above HIV/AIDS).

Development status

PDS0201 is currently in pre-clinical development.

Receive Email Alerts

Join our mailing list to receive the latest news and updates from our team.

Sign up